Original Research

Single-Tablet Regimens in the Treatment of HIV-1 Infection

Author and Disclosure Information




The potency and once-daily dosing of EFV-based regimens ushered in the era of STRs. The list of STRs has now expanded with the introduction of an RPV-based STR and, lately, 3 different INSTI-based STRs. In the current HHS guidelines, only the INSTI-based STRs are included in the recommended list, mostly because of poor tolerability of EFV/TDF/FTC and lower efficacy of RPV/TDF/FTC in patients with high baseline viremia. In general, the safety profile of STRs has been improving with newer iterations. Their main advantages are convenience, simplicity and improvements in adherence, and possibly reductions in medication errors. Due to these advantages, the percentage of patients on STRs is likely to continue rising. Further expansions of the ART armamentarium may include the development of boosted PI-based STRs as well as novel delivery strategies, such as long-acting injectable regimens. 55 In the meantime, clinicians should develop a greater familiarity with the use of the currently available STRs.

Click here to read the digital edition.


Recommended Reading

Hepatitis infection raises non-Hodgkin lymphoma risk in HIV patients
Federal Practitioner
IHS Program Targets HIV/AIDs in Young Natives
Federal Practitioner
Ryan White Program Announces New Funding Grants
Federal Practitioner
Sexually Transmitted Disease Cases Hit a High
Federal Practitioner
HIV/AIDS Data Trends
Federal Practitioner